



Association between *PON1*-rs662 Gene Polymorphism and Diabetic Retinopathy in Population of the Qom, Iran

Fateme Sabbaghian Bidgoli ¹, Abasalt Hosseinzadeh Colagar ¹, Majid Tafrihi ^{1*} and Roohollah Nakhaei Sistani ^{2*}

1. Department of Molecular and Cell Biology, Faculty of Sciences, University of Mazandaran, Babolsar, Mazandaran, Iran

2. Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Isfahan, Iran

* Corresponding authors:

Majid Tafrihi, Ph.D., Department of Molecular and Cell Biology, Faculty of Science, University of Mazandaran, Babolsar, Mazandaran, Iran

Roohollah Nakhaei Sistani, Ph.D., Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Isfahan, Iran

Tel/Fax: +98 11 35305252, 31 55912397

E-mail:

m.tafrihi@umz.ac.ir, r.nakhaei@kashanu.ac.ir

Received: 4 May 2023

Accepted: 20 Jul 2023

Abstract

Background: Diabetic retinopathy is the most severe diabetic microvascular complication that causes changes in the vessel wall. One of the genes involved in this disease is *PON1*, which encodes paraoxanase1 protein in liver and kidney. It might regulate inflammatory and microvascular responses to the disease. The rs662 T>C is one of the single nucleotide polymorphisms of this gene that changes glutamine to arginine at position 192.

Methods: In this study, 300 samples were collected, including 100 healthy and 100 diabetics without retinopathy, and 100 diabetics retinopathies were studied and their age range was from 30 to 80 years. Then 2.5 ml of blood was collected from all relevant individuals in tubes containing EDTA_{Na2}. This polymorphism was examined by tetra-ARMS PCR.

Results: Results showed that there is no significant correlation between genotypes and alleles related to *PON1* and Diabetes (CC genotype: p=0.609; C allele: p=0.228). On the other hand, an association was observed between *PON1* and diabetic retinopathy (CT+CC genotype: p<0.001; CT allele: p<0.001). Considering that the Polyphen database examined the changes caused by replacing the amino acid arginine instead of glutamine at position 129 on the protein, it does not consider these changes dangerous and has introduced this polymorphism as benign.

Conclusion: Based on the findings of this study, the rs662 locus could be considered as one of the molecular markers in future research.

Keywords: Diabetic angiopathies, Diabetic retinopathy, Polymerase chain reaction, Polymorphism, *PON1*

To cite this article: Sabbaghian Bidgoli F, Hosseinzadeh Colagar A, Tafrihi M, Nakhaei Sistani R. Association between *PON1*-rs662 Gene Polymorphism and Diabetic Retinopathy in Population of the Qom, Iran. Avicenna J Med Biotech 2023;15(4):253-257.

Introduction

Diabetes mellitus is the most common noncommunicable disease worldwide. It is among the leading causes of death in all socioeconomic circumstances ¹. Diabetic Retinopathy (DR) is known as a major complication of diabetes mellitus, which is a leading cause of visual loss. DR is characterized by vascular abnormalities in the retina ². Clinically, DR includes two stages: Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is the early stage of DR. In this stage, retinal pathologies such as hemorrhages and microaneurysms are detectable. However, neovascularization occurs in PDR ³. A meta-analysis study showed that the inci-

dence of diabetic retinopathy ranges from 22 to 127% ⁴. In addition, the prevalence of DR in Iranian diabetic patients is 30% ⁵. The pathophysiology of this disease is complex and has not been fully understood. Oxidative stress is implicated in hyperglycemia-induced abnormalities in the retina ⁶. In recent years, it is generally believed that genetic factors are involved in the occurrence, prevention, and treatment of DR.

Today, various polymorphisms in the promoter or coding regions have been documented in the paraoxanase 1 (*PON1*) gene ⁷. *PON1*, a calcium-dependent enzyme is known as a serum esterase/lactonase which is synthesized in liver ⁸. *PON1*, a polymorphic protein

prevents low-density lipoprotein oxidation in diabetes⁹. PON1 is an HDL-associated protein that hydrolyzes oxidized LDL-cholesterol and exerts potential athero-protective effects¹⁰. However, few studies reported a relationship between *PON1* polymorphisms with DR. Hampe *et al* demonstrated that the *PON1* R allele is associated with susceptibility to DR¹¹. Another study showed that genotype L/L was significantly associated with DR¹². Therefore, one of the polymorphisms that may play a role in DR is rs662(Q192R), and this study aimed to investigate the relationship between rs662-PON1 gene polymorphism and DR in the Qom's population.

Materials and Methods

Samples

In the case-control study, intravenous blood samples were collected from diabetic patients with retinopathy (n=100), without retinopathy (n=100), and healthy subjects (n=100). The inclusion criteria were age from 30 to 80 years old, and the diagnosis of retinopathy by an optometrist. All blood samples were collected from Qom hospitals in Iran from 2018 to 2022 years. This study was approved by the Ethics Committees of the Mazandaran University of Medical Science (#IR.UMZ.REC.1399.035) and all subjects signed an informed consent form before entering the study.

DNA extraction and PCR-RFLP

Genomic DNA was extracted from leukocytes of the blood samples by a standard salting out method. Ex-

tracted DNA stored at -20°C after determining the relevant concentrations and analysis on gel electrophoresis. PON1-rs662 gene polymorphisms were examined by *tetra*-ARMS PCR. All primers used in this research were designed by a primer design program, Oligo7 (Table 1). Each PCR reaction was performed in a final volume of 20 µl, including 100 ng of genomic DNA, 3.5 µl of 10× solution buffer, 1.5 µl of a 10 µM of four mixed dNTPs, 1.5 µl of 50 mM of MgCl₂, 0.25 µl of 5u/µl *Taq* DNA polymerase (Cinnagene, Co., Iran) and appropriate concentrations of each primer. 1.4 µl, of IF and IR primers and 1.2 µl, of the OR and the OF primers were added to the tubes at a concentration of two picomoles (*pmol*), and after adding 1 µl, of template DNA, finally 3.4 µl, of *Taq* DNA polymerase enzyme was added. After a short vortex and then spinning the samples, the PCR steps of the desired fragments were performed using the thermal cycler: my cycler (Bio-Rad). The amplified PCR products were checked using a primer map in the *tetra*-ARMS, which is shown in figure 1.

Table 1. PCR primer sequences of *PON1*-rs662 locus

Primer name	Oligomer 5'→3'	Tm (°C)
IF	TAAACCCAAATACATCTCCCAGGCTT	57.8
IR	ATCACTATTTTCTTGACCCCTACTTCCG	
OF	TACATTTAGAGAGATTACATACTTGCCA	57.8
OR	TTTAGGAATAGACAGTGAGGAATGCCA	




Figure 1. Different genotypes in tetra-ARMS PCR method. A) Primer map in the *tetra*-ARMS PCR; B) Electrophoresis patterns of genotypes in 2% agarose gel; C) Electropherograms of flanking nucleotides in the three loci.

In silico analysis

In silico analyses were performed to evaluate the potential biological functions of two protomeric indel polymorphisms, rs662, located in the coding region of the *PONI* gene. So, the coding sequence of the *PONI* gene was screened by Polyphen-2, I-Mutant, Panther, PhD-SNP, SNP&GO, and PROVEAN prediction tools.

Statistical analysis

The Hardy-Weinberg equilibrium (HWE) was calculated for groups. All data were analyzed using SPSS software version 16. Differences in the frequency of alleles and genotypes were analyzed using the chi-square test or Fisher's exact test. The association between *PONI* gene polymorphisms and male infertility was estimated by computing the Odds Ratio (OR) and 95% Confidence Intervals (CI) from a logistic regression analysis model after adjustment for age. The $p < 0.05$ was considered statistically significant.

Results

Extraction of the human genome from blood was done by salting out method and to check the quality of extracted DNA, it was run on the agarose gel. Also, the concentration of samples was measured by the spectrophotometric method. Polymorphism genotyping was done by *tetra*-ARMS PCR method. The desired PCR product used four inner and outer primers was run on a 2% gel with an optimal binding temperature of 57.8°C. The 317 bp band is the result of two Outer primers, which can be seen in all samples. The bp band 197 bp is specific to the T allele, which is the wild allele, and the 174 bp band is specific to the C allele, which is the mutant allele. A heterozygous individual has all three bands. The wild allele homozygous individual has two 317 bp and 197 bp bands and the mutant allele homozygous individual has two 317 bp and 174 bp bands (Figure 1).

The analysis of allele frequency distribution of rs662 T>C showed that the frequency of CC, TT, and CT genotypes in healthy groups is 31, 47, and 22%, respectively. The frequency of CC, TT, and CT genotypes in the diabetic group without retinopathy was 30, 49, and 21%, respectively. Moreover, the frequency of CC, TT, and CT genotypes in the DR group was 17, 21, and 62%, respectively (Table 2).

Investigations of the SIFT database, which examines protein function when another amino acid is substituted, indicated that Q192R may affect the protein which requires further investigation. The results of the GO & SNP database showed that Q192R polymorphism is a neutral polymorphism. The Mutant-I database determines protein stability based on energy changes released by amino acid substitutions. According to the result of this database, which reported 88.0:DDG, replacing the amino acid arginine instead of glutamine at position 129, causes a significant decrease in protein stability. This neutral polymorphism was also reported in the PROVEAN database. However, considering that the Polyphen database examined the changes caused by replacing the amino acid arginine instead of glutamine at position 129 on the protein, it does not consider these changes dangerous and has introduced this polymorphism as benign (Table 3).

Discussion

In this study, the relationship between rs662 polymorphism and DR was evaluated in the population of Qom. The results of our study showed that there was a significant relationship between rs662 polymorphism and diabetic retinopathy in the Qom's population. Our finding showed a significant relationship between CT allele and DR. According to our findings, there was no study on the relationship between rs662 polymorphism and DR. DR is the most severe diabetic microvascular

Table 2. Genotypic and allelic frequency of *PONI* gene in C>T rs662 region for healthy and diseased groups

Genotype	Normal (n=100)	DwR (n=100)	OR (95% CI)	p-value	DR (n=100)	OR (95% CI)	p-value
TT	47 (47%)	49 (49%)	Ref	-	21 (21%)	Ref	-
CT	22 (22%)	21 (21%)	0.916 (0.446-1.880)	0.810	62 (62%)	6.307 (3.107-12.8.3)	0.001
CC	31 (31%)	30 (30%)	0.928 (0.489-1.764)	0.820	17 (17%)	1.227 (0.560-2.688)	0.609
CT+CC	53 (53%)	51 (51%)	0.923 (0.530-1.608)	0.777	79 (80%)	3.336 (1.793-6.208)	0.001
T- allele	116 (58%)	119 (59.5%)	Ref	-	104 (52%)	Ref	-
C- allele	84 (42%)	81 (40.5%)	0.940 (0.631- 1.4)	0.761	96 (48%)	1.275 (0.859-1.892)	0.228

OR: Odds Ratio, CI: Confidence Interval, DwR: Diabetic without retinopathy, DR: Diabetic retinopathy.

Table 3. Results from bioinformatics servers

RsID	Polyphen2	I-Mutant3.0	Provean	SNP & GO	PhD-SNP	Panther
rs662 (Q192R or T>C)	Benign	Large decrease instability	Neutral	Neutral	Neutral	Neutral

complication. Therefore, in line with the results, some studies showed the relationship between polymorphism and vascular diseases. The immunohistochemical analysis in a study indicated that gene expression of *PON1* was decreased in atherosclerotic arteries compared to normal arteries. There was a significant relationship between PON1 Q192R (rs662) polymorphism and the risk of Coronary Artery Disease (CAD). Moreover, 192R allele carriers had a higher risk of CAD compared with other allele carriers¹³. Deng *et al* reported that rs662 (G>A) was markedly associated with Congenital Heart Defects (CHD) susceptibility compared with healthy subjects. In addition, a G allele was related to an increased risk of CHD¹⁴. Another study demonstrated that C and R alleles were associated with T2DM susceptibility. In addition, the frequency of CC and RR genotype was markedly higher in patients with T2DM compared with healthy subjects. Moreover, CC and RR genotypes were associated with low HDL and higher LDL levels¹⁵. GG genotype of PON1 rs662 was related to an increased risk of CAD in an Indian population. In addition, a higher frequency of the G allele was also observed in CAD patients compared with control subjects¹⁶. However, a study reported that there was no association between *PON1* (rs662) polymorphisms and diabetic dyslipidemia¹⁷. The relationship between the PON1 rs662 polymorphism and CHD may be mediated by abnormal Ox-LDL and lipid levels caused by the R allele¹⁸. The inconsistent findings in the relationship between Q192R polymorphism with the increased risk of vascular impairment may be due to variations in genotyping methods, sample size, pathological states, and diverse environmental effects. Oxidative stress plays an important role in chronic inflammatory diseases such as CAD, diabetes, and DR. *PON1* has a protective function due to its anti-inflammatory and antioxidant role in the body^{19, 20}. *PON1* is mainly synthesized in liver. It is associated with HDL. Decreased *PON1* levels lead to increasing ox-LDL in blood, thereby increasing the susceptibility to vascular dysfunction^{21,22}. *PON1* rs662 gene polymorphism is involved in modulating the *PON1* enzyme²³. The R allele variant is implicated in the less active isoform of *PON1* against lipoprotein oxidation, and higher ox-LDL, triglycerides, and LDL-C, which lead to an increased risk of vascular dysfunction^{24,25}. Moreover, the inter-relationship between the *PON1* and *PON2* genes may affect glycaemic control in patients with diabetic retinopathy²⁶.

The analysis of bioinformatics software showed that this polymorphism causes a large decrease in protein stability. This decrease in stability by affecting the function of the *PON1* enzyme can be a factor for the lack of hydrolysis of organophosphates. *PON1* enzyme has an antioxidant role. Since the high level of Reactive Oxygen Species (ROS) plays a role in the pathogenesis of various diseases such as diabetes and heart failure and causes the destruction of the retinal capillar-

ies and hippocampus, this factor can be a reason for the development of DR. The limitation of our study can be the relatively small sample size.

Conclusion

The findings of this research showed that there is a significant relationship between the mutant C allele in three groups: healthy, diabetic without retinopathy, and DR causing such a result in this research. Therefore, larger population in the future research are recommended to conduct such a study.

Acknowledgement

We appreciate all the colleagues who have worked with us in this study. We would like to extend our thanks to the University of Mazandaran (Iran) for the financial support, dedicated to the MSc candidate of Fateme Sabbaghian Bidgoli (#IranDoc1602456). Thanks to our colleagues: Mr. Mohammadkazem Heydari & Ms. Zahra Shirzad (from the Molecular and Cell biology lab, University of Mazandaran).

Conflict of Interest

There is no conflict of interest to declare.

References

1. Khan SZ, Ajmal N, Shaikh R. Diabetic retinopathy and vascular endothelial growth factor gene insertion/deletion polymorphism. *Can J Diabetes* 2020;44(3):287-91.
2. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. *J Diabetes Res* 2016;2016:2156273.
3. Wang W, Lo AC. Diabetic retinopathy: pathophysiology and treatments. *Int J Mol Sci* 2018;19(6):1816.
4. Sabanayagam C, Banu R, Chee ML, Lee R, Wang YX, Tan G, et al. Incidence and progression of diabetic retinopathy: a systematic review. *Lancet Diabetes Endocrinol* 2019;7(2):140-9.
5. Nezhad GSM, Razeghinejad R, Janghorbani M, Mohamadian A, Jalalpour MH, Bazdar S, et al. Prevalence, incidence and ecological determinants of diabetic retinopathy in Iran: systematic review and meta-analysis. *J Ophthalmic Vis Res* 2019;14(3):321.
6. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. *Redox Biol* 2020;37:101799.
7. Hofer SE, Bennetts B, Chan AK, Holloway B, Karschikus C, Jenkins AJ, et al. Association between PON 1 polymorphisms, PON activity and diabetes complications. *J Diabetes Complicat* 2006;20(5):322-8.
8. Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. *Vasc Health Risk Manag* 2018;14:137-43.
9. Tomás M, Latorre G, Sentí M, Marrugat J. The antioxidant function of high density lipoproteins: a new para-

- digm in atherosclerosis. *Rev Esp Cardiol (English Edition)* 2004;57:557-69.
10. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. *Curr Opin Lipidol* 2004;15:261-7.
 11. Hampe M, Mogharekar M. Paraoxonase1 activity, its Q192R polymorphism and diabetic retinopathy in type 2 diabetes mellitus. *Int J Biomed Adv Res* 2014;5:35-40.
 12. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. *J Clin Endocrinol Metab* 1998;83(7):2589-92.
 13. Liu T, Zhang X, Zhang J, Liang Z, Cai W, Huang M, et al. Association between PON1 rs662 polymorphism and coronary artery disease. *Eur J Clin Nut* 2014;68(9):1029-35.
 14. Deng Z, Xiang H, Gao W. Significant association between paraoxonase 1 rs662 polymorphism and coronary heart disease. *Herz* 2020;45(4):347-55.
 15. Wamique M, Ali W, Himanshu D. Association of SRB1 and PON1 gene polymorphisms with type 2 diabetes mellitus: A case control study. *Int J Diabetes Dev Ctries* 2020;40:209-15.
 16. Kumar R, Saini V, Kaur C, Isser H, Tyagi N, Sahoo S. Association between PON1 rs662 gene polymorphism and serum paraoxonase1 level in coronary artery disease patients in Northern India. *Egypt J Med Hum Genet* 2021;22:1-8.
 17. Vardarli AT, Harman E, Çetintaş VB, Kayıkçıoğlu M, Vardarli E, Zengi A, et al. Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia. *Anatol J Cardiol* 2017;17(4):313-21.
 18. Luo Z, Pu L, Muhammad I, Chen Y, Sun X. Associations of the PON1 rs662 polymorphism with circulating oxidized low-density lipoprotein and lipid levels: a systematic review and meta-analysis. *Lipids Health Dis* 2018;17(1):1-13.
 19. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. *Circulation* 2002;106(4):484-90.
 20. Gupta N, Singh S, Maturu, VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. *PLoS One* 2011; 6(5):e17805.
 21. Nus M, Frances F, Sánchez-Montero J, Corella D, Sánchez-Muniz F. We-W44: 4 arylesterase activity and HDL-cholesterol levels are dependent on the PON 55M and PON 192R polymorphisms. *Atherosclerosis* 2006;3:333.
 22. Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, Freitas I, Mendonça MI, Nascimento H, et al. Main determinants of PON1 activity in hemodialysis patients. *Am J Nephrol* 2012;36(4):317-23.
 23. Mucientes A, Fernández-Gutiérrez B, Herranz E, Rodríguez-Rodríguez L, Varadé J, Urcelay E, et al. Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis. *Clin Rheumatol* 2019;38(5):1329-37.
 24. Mackness MI, Arrol S. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density. *Lancet* 1997;349(9055):851-2.
 25. Siller-López F, Garzón-Castaño S, Ramos-Márquez ME, Hernández-Cañaveral I. Association of paraoxonase-1 Q192R (rs662) single nucleotide variation with cardiovascular risk in coffee harvesters of central Colombia. *J Toxicol* 2017;2017:6913106.
 26. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. *Clin Sci* 2000;98(3):355-63.